Eli Lilly and Company (LLY)
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Eli Lilly (LLY) closed at $935.58, indicating a -1.98% shift from the previous trading day.
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh
Eli Lilly And Company (NYSE: LLY) shares are down approximately 1% Thursday despite FDA approval of its oral weight-loss drug Foundayo on Wednesday, as geopolitical tensions weigh on broader markets.
Lilly (LLY) Surges 3.8%: Is This an Indication of Further Gains?
Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker's efforts to expand its foothold in the lucrative obesity market.
Eli Lilly weight loss pill Foundayo approved by FDA, shares rise
Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity or those who are overweight with weight-related medical conditions, sending its shares more than 5% higher on Wednesday afternoon.
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash, with a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones. The acquisition adds Centessa's sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly's neuroscience business.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
